FCX-007 (dabocemagene autoficel; see below for FCX-007 description)

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Recessive Dystrophic Epidermolysis Bullosa

Drug Information

Target Indication

Recessive Dystrophic Epidermolysis Bullosa

Clinical Trial

Last updated: 1/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

CSTL

CASTLE BIOSCIENCES INC

Related Pipeline

Dystrophic Epidermolysis Bullosa

Bilateral Nasolabial Fold Wrinkles

Acne Scarring of the Face

Dysphonia Resulting From Vocal Fold Scarring

Epidermolysis Bullosa